Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

CHMP recommends approval of linagliptin for type 2 diabetes

June 27, 2011

Once-weekly exenatide approved in E.U. for type 2 diabetes

June 22, 2011

Cebix advances C peptide replacement therapy for chronic complications of diabetes

June 22, 2011

EMA committee accepts for review PROLOR's PIP for long-acting human growth hormone

June 22, 2011

MK-0916 reduces HbA1c and body weight in phase II trial in diabetes/metabolic syndrome

June 22, 2011

Merck & Co. patents new GPR119 receptor agonists

June 22, 2011

Plerixafor is beneficial in patients with myelokathexis

June 22, 2011

New GPR119 receptor agonists claimed by Pfizer

June 21, 2011

Targeted secretion inhibitors SXN-101000 and SXN-101742 inhibit growth hormone secretion in vivo

June 21, 2011

Novo Nordisk issues reminder of risks associated with Victoza

June 20, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...